EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, and Biological Evaluation of BODIPY-Caged Resiquimod as a Dual-Acting Phototherapeutic

Eslam Roshdy iD, Haruto Taniguchi, Yoki Nakamura, Haruko Takahashi iD, Yutaka Kikuchi iD, Ismail Celik iD, Elsayed S I Mohammed, Yasuhiro Ishihara, Norimitsu Morioka, Manabu Abe iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Eslam Roshdy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, Higashi-Hiroshima City, Hiroshima 739-8526, Japan. Hauptthemen laut MEDLINE: Boron Compounds, Imidazoles, Drug Design, Photosensitizing Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resiquimod, an imidazoquinoline scaffold, exhibits potent immunotherapeutic activity but is associated with off-target effects, limiting its clinical utility. To address this limitation, we developed a novel BODIPY-caged resiquimod that is responsive to red light, combining photocaging and photodynamic therapy functionalities. Molecular docking studies guided identification of the optimal caging site for resiquimod, effectively masking its immune activity. BODIPY-caged resiquimod remained inactive under dark conditions, effectively masking resiquimod's immunostimulatory effects. However, red light irradiation precisely uncaged resiquimod, inducing robust immune activation, even in the presence of N-acetyl cysteine as an antioxidant. Notably, the attachment of resiquimod to BODIPY reduced the dark toxicity typically associated with BODIPY as a photosensitizer. In 3D spheroid models of HeLa and A549 cells, BODIPY-caged resiquimod demonstrated spatiotemporal control over cytotoxicity, significantly enhancing cell death only upon irradiation. This dual-function therapeutic approach highlights a "win-win" strategy: precise, red-light-mediated control of immune activation and photodynamic efficacy with reduced collateral toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron CompoundsImidazolesDrug DesignPhotosensitizing AgentsPhotochemotherapyHumansAnimalsMolecular Docking SimulationHeLa CellsMiceA549 CellsAntineoplastic AgentsStructure-Activity Relationship

Substanzen

Boron CompoundsImidazoles4,4-difluoro-4-bora-3a,4a-diaza-s-indacenePhotosensitizing AgentsresiquimodAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, Higashi-Hiroshima City, Hiroshima 739-8526, Japan.
  • Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
  • Department of Pharmacology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima 734-8553, Japan.
  • Graduate School of Integrated Sciences for Life, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, Hiroshima 739-8526, Japan.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.
  • Avian Research Center, King Faisal University, Al Hofuf, Al-Ahsa 31982, Saudi Arabia.

ORCID-Profile: Eslam Roshdy, Haruko Takahashi, Yutaka Kikuchi, Ismail Celik, Manabu Abe

Förderung

  • Japan Science and Technology Corporation

Zitieren

APA

Roshdy, E., Taniguchi, H., Nakamura, Y., Takahashi, H., Kikuchi, Y., Celik, I., Mohammed, E. S. I., Ishihara, Y., Morioka, N., & Abe, M. (2025). Design, Synthesis, and Biological Evaluation of BODIPY-Caged Resiquimod as a Dual-Acting Phototherapeutic. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02606

Vancouver

Roshdy E, Taniguchi H, Nakamura Y, Takahashi H, Kikuchi Y, Celik I, et al. Design, Synthesis, and Biological Evaluation of BODIPY-Caged Resiquimod as a Dual-Acting Phototherapeutic. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02606

BibTeX
@article{Roshdy2025,
  author = {Roshdy, Eslam and Taniguchi, Haruto and Nakamura, Yoki and Takahashi, Haruko and Kikuchi, Yutaka and Celik, Ismail and Mohammed, Elsayed S I and Ishihara, Yasuhiro and Morioka, Norimitsu and Abe, Manabu},
  title = {Design, Synthesis, and Biological Evaluation of BODIPY-Caged Resiquimod as a Dual-Acting Phototherapeutic},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02606}
}
Kostenlos starten →